HomeMarketsEarningsLLY Earnings: How an Oral GLP-1 Pill Could Supercharge Revenue

LLY Earnings: How an Oral GLP-1 Pill Could Supercharge Revenue

Christine Short and Scott Zari cover Eli Lilly (LLY) earnings and the future of GLP-1 drugs. Christine emphasizes the global demand for these drugs, as evidenced by higher international revenue, and what a daily oral GLP-1 pill could do for the company. Scott looks at Eli Lilly’s market share in the weight loss sector, calling it a “two horse race” between them and Novo Nordisk (NVO).

The Watch List

31 Oct 2025

SHARE

ON AIR
5:00 am
Next Gen Investing
replay
education
12:00 am
Your First Trade
REPLAY
education
12:30 am
Your First Trade
REPLAY
education
1:00 am
Inside the Mind of a Trader
REPLAY
education
1:30 am
Inside the Mind of a Trader
REPLAY
education
2:00 am
Inside the Mind of a Trader
REPLAY
2:30 am
Market Overtime
REPLAY
3:00 am
The Wrap
REPLAY
4:00 am
Fast Market
REPLAY
ON AIR
5:00 am
Next Gen Investing
REPLAY
6:00 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Fast Market
REPLAY
9:00 am
Next Gen Investing
REPLAY
education
10:00 am
Your First Trade
REPLAY
education
10:30 am
Your First Trade
REPLAY
education
11:00 am
Your First Trade
REPLAY
education
11:30 am
Your First Trade
REPLAY
education
12:00 pm
Your First Trade
REPLAY
education
12:30 pm
Your First Trade
REPLAY
education
1:00 pm
Your First Trade
REPLAY
education
1:30 pm
Your First Trade
REPLAY
education
2:00 pm
Your First Trade
REPLAY
education
2:30 pm
Your First Trade
REPLAY
3:00 pm
Market Overtime
REPLAY
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
7:00 pm
Market Overtime
REPLAY
7:30 pm
Market Overtime
REPLAY
8:00 pm
The Wrap
REPLAY
9:00 pm
Market Overtime
REPLAY
9:30 pm
Market Overtime
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Next Gen Investing
REPLAY

Schwab Network's Newsletters

Daily insights for every investor